Menarini Group and Insilico Medicine Enter into Exclusive Global License Agreement for New KAT6 Inhibitor for Potential Breast Cancer Treatments and Other Oncology Indications
Florence, Italy and New York (ots/PRNewswire) – Menarini Group (“Menarini”) is a leading international manufacturer of pharmaceuticals and diagnostic products, Stemline Therapeutics, Inc. (“Stemline”) a wholly owned subsidiary of Menarini Group, dedicated to helping cancer patients with transformative oncology therapies. Together with Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-powered clinical-stage drug discovery biotechnology company, … Read more